MBRX MBRX
Company Profile ↓Company Overview
MBRX (MBRX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -97.73% |
| 6 Months: | -90.69% |
| 3 Months: | -84.34% |
| 1 Month: | -83.19% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)16.86 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 17 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -222.75K | -321.00K | -724.00K | -1.42M | -1.53M | -1.32M | -2.40M | -2.64M | -5.46M | -2.59M | -4.57M | -3.63M | -4.51M | -5.06M | -5.03M | -6.15M | -6.09M | -5.52M | -6.16M | -7.07M | -7.43M | -9.08M | -8.35M | -6.41M | -5.95M | -6.68M | -6.18M | -7.13M | -5.94M | -5.72M | -5.91M | -7.87M |
| Net Income | -224.31K | -332.00K | -739.00K | -1.43M | -329.00K | -3.42M | -2.87M | -1.93M | -5.12M | -2.04M | -4.04M | -1.22M | -4.14M | -1.21M | -10.11M | -3.40M | -4.45M | -4.24M | -4.38M | -6.87M | -6.78M | -8.61M | -7.92M | -5.98M | -5.61M | -6.42M | -6.01M | -7.02M | -5.90M | -17.81M | -25.40M | -12.85M |
| R&D Expense | 38.41K | 15.00K | 105.00K | 497.00K | 683.00K | 515.00K | 1.06M | 1.24M | 4.23M | 1.33M | 2.93M | 2.10M | 2.79M | 3.21M | 3.33M | 4.43M | 4.11M | 3.04M | 4.09M | 4.62M | 4.20M | 5.96M | 5.69M | 3.89M | 3.28M | 4.25M | 4.09M | 4.93M | 3.44M | 3.60M | 3.74M | 5.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.88M | -8.65M | -15.03M | -17.52M | -19.74M | -22.97M | -30.64M | -29.63M | -26.64M | -25.10M |
| Net Income | -3.93M | -9.80M | -11.88M | -13.21M | -17.36M | -15.89M | -29.02M | -29.77M | -26.05M | -33.56M |
| R&D Expense | 1.50M | 4.54M | 9.73M | 11.01M | 12.76M | 14.42M | 18.97M | 19.49M | 17.73M | 15.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 28.09K | 16.39M | 19.48M | 19.59M | 25.23M | 29.03M | 84.09M | 57.42M | 38.22M | 16.93M | 22.13M |
| Total Equity | - | -745.00K | 14.96M | 17.12M | 14.27M | 15.57M | 17.76M | 78.99M | 52.19M | 30.93M | 11.21M | 15.01M |
| Cash & Equivalents | 0 | 28.00K | 5.01M | 7.71M | 7.13M | 10.73M | 15.17M | 70.90M | 43.15M | 23.55M | 4.28M | 8.88M |
| Total Liabilities | - | 772.79K | 1.43M | 2.37M | 5.31M | 9.66M | 11.27M | 5.10M | 5.23M | 12.14M | 5.72M | 7.12M |
| Current Liabilities | - | 772.79K | 1.34M | 2.21M | 3.88M | 3.57M | 2.92M | 3.62M | 4.82M | 6.82M | 5.36M | 6.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.77M | -7.32M | -12.20M | -17.20M | -17.77M | -18.95M | -27.64M | -23.59M | -23.86M | -22.73M |
| Investing Cash Flow | -121.00K | -28.00K | -417.00K | -51.00K | -374.00K | -19.00K | -67.00K | -124.00K | -13.00K | 0 |
| Financing Cash Flow | 8.87M | 10.06M | 12.04M | 20.85M | 22.55M | 74.72M | -23.00K | 4.14M | 4.63M | 27.28M |
| Capital Expenditure | -21.00K | -28.00K | -417.00K | -52.00K | -376.00K | -19.00K | -67.00K | -124.00K | -13.00K | -0 |
| Free Cash Flow | -3.79M | -7.35M | -12.62M | -17.25M | -18.15M | -18.97M | -27.71M | -23.71M | -23.88M | -22.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | -26.2% | -57.3% | -83.2% | -84.8% | -97.7% | -20.1% | -55.6% | -96.3% | -232.4% | -223.6% |
| ROCE % | -25.8% | -50.1% | -95.7% | -80.9% | -75.6% | -28.5% | -58.2% | -94.4% | -230.3% | -164.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBRX
Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPdlh3ZS1KTjZfUE1JUFJSMnZackFMQXlERy1jNHRLbHBreVMyckh4ZE9PWmp5T25MY0dTb3lvVUtKd2FjNEFSRUdNQmhwRFFtTWlYNnpDdTJWd0VEcF9aOWlCMkpZb0ZJdzNXdm1xYnJxWFF2WjY4WGlTZzNKdXk4ZDF3Vm1FQQ?oc=5" t…
Moleculin Biotech, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOVG4tWmZhYmdHckdCRXJKRXoyNDNmZUl2bjJQVjVBQWV1SmEwd25uRnFjVW5wWlZ3dzJRQWtfajRTNDJTSTBfOWlSWW5yMllBa0FzRDFLaWsxb19xSUlySG1NaWprUWdOeEEyaFBfRHBQOUdVMGxIb0RGb3RPcmxTbmVObTI1ZDI4VzZ3N0…
Market Movers | Winners: FWAC, REPL, MGRX | Losers: KPTI, BIOA, MBRX - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQXzBCRUREcDlWY0c1eXFTMDlSWUQydGFPdUFkTnFlclRqdV9sRnF3R0ZGOGp0aWZEWnhMaTdXcnVuQXV4cDdkbklQMEJXOFo3NFFqam16ZC1vTXVOcWwxX0pfNEEtenNaZ1RKZVlQcUtTdHc2MzF1T2tGMllYMVMtWEZ0dG1aZWszLTBBZl…
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxQOWRyOXFBVDdjdUw1aVZSX2VSckJGR1Jac2hiWXVFS2loVk1qUXhuN2ZaQ2ZUYmh1ZVlqTzZ5eGJoRS1jVDF6Z3BHbnotN0otZjhKV05IbFNqMW5VXy1VMjEyQ2tGWUVETlNNbTFQMWZPUV9jRHFBNEIxZTUzalFrS2tCSHVrZmt1bzJ6Q2…
Moleculin Biotech Stock Is Sinking Friday: What's Going On? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQcTdncHI0R0JqWDZZWDNXS1M3WnpnOHJtcVJXRnBwRU5uLXRlbGNuX29nS0E5LXpzTkU4ZVBTVWh1aHJqdElfdTB4cFl0b3BmaWktTGtxSVhyT0gyWmduQUVTTGVZZGRzUkZCZnZfWFdHWUx4eDQwZkpaY0Q3TFhiSTNCc0pfdm1DRGRLZk…
Moleculin Biotech (MBRX) Reports Preliminary Phase 2/3 Trial Dat - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOOHlwY0FxZ3JTS01lZ054NDQ2T21CQVlVU180aEduUTF6bV9VYWszSmVkeGhhaFZqNk9NVW1VVHoxZUw5RUdQeTQ1d0RCQUxRQm93RURPQVotVktFdkx3Wm5DTDFJWFYtVkxEM2ZDUURkT0FydHo4bFpoSmxveGNRaFRnbjBuWnQ5b2lTWW…
MBRX — Frequently Asked Questions
What is the current share price of MBRX?
As of 2026-08-05 17:25 PDT, MBRX trades at $0.39 on NASDAQ/NYSE. Its 52-week range is $0.39 to $17.15.
Is MBRX a good stock to buy?
This page provides a data-driven analysis of MBRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.